New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:01 EDTLPL, WFC, USB, STAA, AXLL, BSMX, BSX, EVER, VMW, SYMC, FBNC, FIBK, ACHN, ROST, YZC, UAL, SSYS, BBD, YELP, PTENOn The Fly: Analyst Upgrade Summary
Axiall (AXLL) upgraded to Buy from Neutral at BofA/Merrill... Banco Bradesco (BBD) upgraded to Outperform from Neutral at Credit Suisse... First Bancorp (FBNC) upgraded to Outperform from Market Perform at Raymond James... STAAR Surgical (STAA) upgraded to Outperform from Market Perform at William Blair... Stratasys (SSYS) upgraded to Overweight from Neutral at JPMorgan... Symantec (SYMC) upgraded to Outperform from Market Perform at BMO Capital... U.S. Bancorp (USB) upgraded to Neutral from Underweight at Atlantic Equities... United Continental (UAL) upgraded to Outperform from Market Perform at Raymond James... VMware (VMW) upgraded to Buy from Neutral at Sterne Agee... Wells Fargo (WFC) upgraded to Neutral from Underweight at Atlantic Equities... Yanzhou Coal (YZC) upgraded to Neutral from Underperform at Credit Suisse... EverBank Financial (EVER) upgraded at Sterne Agee... LG Display (LPL) upgraded to Buy from Neutral at Nomura... Ross Stores (ROST) upgraded at RBC Capital... Boston Scientific (BSX) upgraded at Bernstein... Achillion (ACHN) upgraded to Buy from Hold at Maxim... Patterson-UTI Energy (PTEN) upgraded to Overweight from Equal Weight at Stephens... Santander Mexico (BSMX) upgraded to Buy from Neutral at UBS... Yelp (YELP) upgraded to Outperform from Market Perform at JMP Securities... First Interstate (FIBK) upgraded to Buy from Neutral at Sterne Agee.
News For AXLL;BBD;FBNC;STAA;SSYS;SYMC;USB;UAL;VMW;WFC;YZC;EVER;LPL;ROST;BSX;PTEN;ACHN;BSMX;YELP;FIBK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 20, 2015
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTBSXBoston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on March 27 at 11 am.
06:44 EDTBSXBoston Scientific initiated with an Outperform at Raymond James
Subscribe for More Information
06:16 EDTYELP2012 antitrust report calls Google harmful to market, WSJ says
Subscribe for More Information
06:11 EDTYELPYelp selloff yesterday a buying opportunity, says Wunderlich
Subscribe for More Information
06:08 EDTYELPStocks with implied volatility below IV index mean; LL YELP
Subscribe for More Information
March 19, 2015
13:51 EDTYELPYelp weakness a buying opportunity, says Cowen
Subscribe for More Information
11:53 EDTWFC, USBU.S. banks face headwinds in unloading oil loans, WSJ says
Subscribe for More Information
10:12 EDTYELPYelp puts active after plans for critical documentary announced
Subscribe for More Information
09:43 EDTYELPYelp falls after plans for critical documentary announced
Subscribe for More Information
March 18, 2015
09:17 EDTBSMXSantander Mexico acquirig a portion of its loan portfolio from Scotiabank Mexico
Subscribe for More Information
05:39 EDTBSXSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:13 EDTBSXBoston Scientific announces FDA, CE Mark approval of EMBLEM S-ICD system
Boston Scientific has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator, or S-ICD, system. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest, yet leaves the heart and vasculature untouched, minimizing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May and subsequent U.S. launch planned for the third quarter of 2015.
14:55 EDTVMWVMware to face more competitive process for DOD contract, says Stifel
After government websites indicated that Citrix (CTXS), Amazon (AMZN) and others succeeded in getting the DoD to reconsider its awarding of a $1.6B, five-year contract to VMware (VMW), Stifel said it doesn't think VMware has necessarily lost the opportunity, but that the company will now likely face a more competitive bidding process to win the deal. The firm view this example as supporting its concerns that VMware's steps to become a more strategic vendor have the potential to be as much of a threat as an opportunity and Stifel maintains its Hold rating on the stock.
14:43 EDTVMWVMware award from DISA canceled after protest, siliconANGLE reports
On March 12, the Defense Information Security Agency, or DISA, reversed a decision to award VMware (VMW) with a $1.6B contract following protests by Amazon Web Services (AMZN), Citrix Systems (CTXS), and others, reported siliconANGLE. A government posting noted that "Amendment 0002 is issued to cancel the request for proposal to further analyze the government's needs." Reference Link
09:06 EDTUALBoeing delivers first 787-9 Dreamliner assembled at North Charleston facility
Subscribe for More Information
07:12 EDTVMWDeutsche Messe to hold a conference
CeBIT 2015 is being held in Hannover, Germany on March 15-20.
March 16, 2015
13:16 EDTBSXAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
09:22 EDTBSXOn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTBSXBoston Scientific Watchman indication 'very favorable,' says Bernstein
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use